Cyberonics to start VNS (vagus nerve stimulation) migraine trial in the US:
This article was originally published in Clinica
Executive Summary
The US FDA has given Cyberonics the go-ahead to begin a pilot study to assess its implantable vagus nerve stimulation (VNS) device as a treatment for chronic migraine headache. The firm's NeuroCybernetic Prosthesis will be tested in 30 patients at four medical centres. It will be used to provide left cervical (neck area) VNS therapy in a similar fashion to the way it is used in patients with epilepsy, depression and Alzheimer's disease, says the Houston, Texas company. The US National Headache Foundation says that there are 28 million migraine sufferers in the US.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.